МАЛЛИК Адам (US),КРУК Розанна М. (US),ГРЭХЕМ Марк Джей. (US),ДОБИ Кеннет В. (US),БЭЛЛ Томас А. (US),ЛИ Ричард (US)
申请号：
RU2013153147/10
公开号：
RU2013153147A
申请日:
2012.04.27
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. The use of a compound aimed at ApoCIII for a) increasing HDL levels and / or improving the ratio of TG to HDL, thereby preventing, slowing or facilitating the occurrence of a cardiovascular disease, disorder, condition or symptom, or the onset of a cardiovascular disease, disorder , a condition or its symptom in an animal； b) an increase in HDL levels and / or an improvement in the ratio of TG to HDL, thereby reducing the risk of a cardiovascular disease, disorder, condition or symptom in an animal； c) increased ia clearance of fats, clearance of chylomicron triglycerides and / or clearance of triglycerides after meals； and / or d) treatment, prophylaxis, retardation and / or facilitation of the course of pancreatitis2. The use according to claim 1, characterized in that the animal suffers or is at risk of hypertriglyceridemia. 3. The use according to claim 2, characterized in that the level of triglycerides in the animal is in the range of 100-200 mg / dl, 100-300 mg / dl, 100-400 mg / dl, 100-500 mg / dl, 200-500 mg / dl, 300-500 mg / dl, 400-500 mg / dl, 500-1000 mg / dl, 600-1000 mg / dl, 700-1000 mg / dl, 800-1000 mg / dl, 900-1000 mg / dl , 500-1500 mg / dl, 1000-1500 mg / dl, 100-2000 mg / dl, 150-2000 mg / dl, 200-2000 mg / dl, 300-2000 mg / dl, 400-2000 mg / dl, 500-2000 mg / dl, 600-2000 mg / dl, 700-2000 mg / dl, 800-2000 mg / dl, 900-2000 mg / dl, 1000-2000 mg / dl, 1100-2000 mg / dl, 1200 -2000 mg / dl, 1300-2000 mg / dl, 1400-2000 mg / dl or 1500-2000 mg / dl. 4. The use according to claim 2, characterized in that hypertriglyceridemia refers to Fredericksonian type II, IV or V.5. The use according to any one of paragraphs. 1-4, characterized in that the animal has a genetic defect leading to hypertriglyceridemia, where the genetic defect is a heterozygous lipoprotein lipase deficiency or ApoCIII.6 polymorphism. Application by1. Применение соединения, нацеленного на ApoCIII, дляа) повышения уровней ЛПВП и/или улучшения соотношения ТГ к ЛПВП, посредст
